PAN02 PANCREATIC TUMOR MODELS CARRYING THE GFP MARKER IN MICE
- Authors: Akopov S.B.1, Snezhkov E.V.1, Konovalova M.V.1, Kostromina M.A.1, Esipov R.S.1, Svirshchevskaya E.V.1
-
Affiliations:
- Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
- Section: Joint Immunology Forum 2024
- URL: https://rusimmun.ru/jour/article/view/16858
- DOI: https://doi.org/10.46235/1028-7221-16858-PPT
- ID: 16858
Cite item
Full Text
Abstract
Abstract
Animal tumor models are used for preclinical studies of drugs and cancer therapy. The aim of this work was to analyze the growth of murine pancreatic tumor cells Pan02, carrying GFP marker, injected subcutaneously (s.c.), intraperitoneally (i.p.) or orthotopically into the pancreas (ortho) of C57BL/6 mice. Mice were injected with 2´105 cells: s.c. in the right flank; i.p. with a syringe into the abdominal cavity, or ortho surgically under the pancreas capsule. The weight of mice was determined in the dynamics of tumor growth, and blood serum was taken to analyze the antibody response to the GFP reference protein. At the 2nd and 4th weeks of tumor growth, some mice were slaughtered and the expression of GFP by the tumor cells, as well as the composition of the immune cells in the tumor, were analyzed by flow cytometry and confocal microscopy. It was shown that with the different localization, the pancreatic tumors grew at different rates and lethality. When the tumor was injected i.p., mice lost weight with rapid tumor growth. In the ortho model, the mice increased their weight. Mortality in the s.c. and i.p. groups was comparable. In the s.c. model, the tumor grew slowly to a volume of 200-400 mm3 and stopped growing. There was no mortality in this group during the follow-up period (2 months). The same antibody response to GFP was formed with all injection schemes. The subpopulation composition of immune cells varied greatly in the different models of tumor cell administration. Regardless of the type of immune response, Pan02-GFP cells rapidly suppressed GFP gene expression in vivo. The data obtained showed that murine pancreatic tumor Pan02 is immunogenic and causes the formation of an adaptive immune response. Regardless of the presence or absence of an immune response and elimination of GFP+ cells, the tumor continued to grow in the i.p. and ortho models, but not in the s.c. one, and caused the death of mice. When conducting preclinical studies, it is necessary to use several ways of tumor cell injection to obtain a more objective result.
Keywords
About the authors
Sergei B. Akopov
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Email: sergeyakopov@mail.ru
ORCID iD: 0000-0002-3000-8025
Scopus Author ID: 7005107365
Doctor of Biological Sciences, Leading researcher at the Laboratory of the Structure and Function of Human Genes
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaEugene V. Snezhkov
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Email: cell6370@yandex.ru
ORCID iD: 0000-0001-8421-9728
Scopus Author ID: 6507782618
Ph.D of Chemical Sciences, Senior Researcher at the Laboratory of the Structure and Functions of Human Genes
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaMaryia V. Konovalova
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Email: mariya.v.konovalova@gmail.com
ORCID iD: 0000-0003-3719-7567
Scopus Author ID: 36196735900
ResearcherId: F-2886-2017
Ph.D. in Biological Sciences, Researcher at the Department of Immunology
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaMariya A. Kostromina
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Email: kostromasha@mail.ru
ORCID iD: 0000-0001-6768-8995
Scopus Author ID: 55123242300
ResearcherId: R-9418-2016
Ph.D. in Biological Sciences, Researcher at the Laboratory of Biopharmaceutical Technologies
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaRoman S. Esipov
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Email: refolding@mail.ru
ORCID iD: 0000-0002-3231-5838
SPIN-code: 3297-9784
Scopus Author ID: 6701850033
ResearcherId: G-4950-2017
Doctor of Biological Sciences, Head of the Laboratory of Biopharmaceutical Technologies.
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaElena V. Svirshchevskaya
Shemyakin-Obchinnikov Institute of Bioorganic Chemistry RAS, 117997, Moscow, Russia
Author for correspondence.
Email: esvir@yandex.ru
ORCID iD: 0000-0002-5647-9298
SPIN-code: 6664-0348
Scopus Author ID: 6701823309
ResearcherId: G-8659-2019
Senior Researcher at the Department of Immunology of the IBH RAS, Candidate of Biological Sciences
Russian Federation, Miklukho-Maklaya str., 16/10, 117997, Moscow, RussiaReferences
- Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Öhlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015, Vol.160, no. 1-2, pp. 324-38. doi: 10.1016/j.cell.2014.12.021
- Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013. Vol. 62, no. 3, pp.339-47. doi: 10.1136/gutjnl-2012-303108.
- Crowley F, Gandhi S, Rudshteyn M, Sehmbhi M, Cohen DJ. Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment. Oncologist. 2023. Vol. 28, no. 6, pp. 486-493. doi: 10.1093/oncolo/oyad044
- Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg. 2022. Vol. 74, no. 1, pp. 35-42. doi: 10.1007/s13304-021-01186-1.
- Ho TTB, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Yamashita T, Mizukoshi E, Kawaguchi K, Wada T, Honda M, Kaneko S, Sakai Y. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer. 2020. Vol. 8, no. 2, pp. e001367. doi: 10.1136/jitc-2020-001367.
- Li K, Tandurella JA, Gai J, Zhu Q, Lim SJ, Thomas DL 2nd, Xia T, Mo G, Mitchell JT, Montagne J, Lyman M, Danilova LV, Zimmerman JW, Kinny-Köster B, Zhang T, Chen L, Blair AB, Heumann T, Parkinson R, Durham JN, Narang AK, Anders RA, Wolfgang CL, Laheru DA, He J, Osipov A, Thompson ED, Wang H, Fertig EJ, Jaffee EM, Zheng L. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 2022, Vol. 40, no. 11, pp. 1374-1391.e7. doi: 10.1016/j.ccell.2022.10.001.
- Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer. 2021, Vol. 1876, no. 1, pp. 188554. doi: 10.1016/j.bbcan.2021.188554.
- McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018, Vol. 24, no. 43, pp. 4846-4861. doi: 10.3748/wjg.v24.i43.4846.
- O'Reilly D, Fou L, Hasler E, Hawkins J, O'Connell S, Pelone F, Callaway M, Campbell F, Capel M, Charnley R, Corrie P, Elliot D, Goodburn L, Jewell A, Joharchi S, McGeeney L, Mukherjee S, Oppong K, Whelan P, Primrose J, Neoptolemos J. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Pancreatology. 2018, Vol. 18, no. 8, pp. 962-970. doi: 10.1016/j.pan.2018.09.012.
- Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, Durini G, Karakoc I, Grier A, Neupert B, Van Court B, Abdelazeem KNM, Yu J, Olimpo NA, Corbo S, Ross RB, Pham TT, Joshi M, Kedl RM, Saviola AJ, Amann M, Umaña P, Codarri Deak L, Klein C, D'Alessandro A, Karam SD. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023, Vol. 41, no. 5, pp. 950-969.e6. doi: 10.1016/j.ccell.2023.04.001.
- Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE, Werba G, Zhang K, Guo Y, Li Q, Akkad N, Lall S, Wadowski B, Gutierrez J, Kochen Rossi JA, Herzog JW, Diskin B, Torres-Hernandez A, Leinwand J, Wang W, Taunk PS, Savadkar S, Janal M, Saxena A, Li X, Cohen D, Sartor RB, Saxena D, Miller G. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018, Vol. 8, no. 4, pp. 403-416. doi: 10.1158/2159-8290.CD-17-1134.
- Svirshchevskaya EV, Konovalova MV, Snezhkov EV, Poltavtseva RA, Akopov SB. Chemokine Homeostasis in Healthy Volunteers and during Pancreatic and Colorectal Tumor Growth in Murine Models. Curr Issues Mol Biol. 2022, Vol. 44, no. 10, pp. 4987-4999. doi: 10.3390/cimb44100339.
- Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ, Banh RS, Paulo JA, Wen KW, Debnath J, Kim GE, Mancias JD, Fearon DT, Perera RM, Kimmelman AC. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020, Vol. 581, no. 7806, pp. 100-105. doi: 10.1038/s41586-020-2229-5.